BR0008182A - Antagonistas do fator de necrose tumoral e seu uso em endometriose - Google Patents

Antagonistas do fator de necrose tumoral e seu uso em endometriose

Info

Publication number
BR0008182A
BR0008182A BR0008182-5A BR0008182A BR0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A
Authority
BR
Brazil
Prior art keywords
antagonists
endometriosis
necrosis factor
tumor necrosis
factor antagonists
Prior art date
Application number
BR0008182-5A
Other languages
English (en)
Inventor
Francesco Borrelli
Mauro D Antonio
Fabrizio Martelli
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0008182A publication Critical patent/BR0008182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Patente de Invenção: "ANTAGONISTAS DO FATOR DE NECROSE TUMORAL E SEU USO EM ENDOMETRIOSE". Antagonistas do fator de necrose tumoral são administrados em doses terapeuticamente eficazes para tratar e/ou prevenir a endometriose. Os antagonistas desta invenção são tipicamente selecionados entre várias classes de moléculas mas de preferência são receptores de TNF solúveis. Os antagonistas são úteis para a regressão de lesões endometriais e, se combinados com outros ingredientes ativos, para melhorar distúrbios relacionados, tal como infertilidade.
BR0008182-5A 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose BR0008182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis
PCT/IB2000/000052 WO2000043031A1 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
BR0008182A true BR0008182A (pt) 2001-11-06

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008182-5A BR0008182A (pt) 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose

Country Status (30)

Country Link
US (2) US6663865B1 (pt)
EP (2) EP1022027A1 (pt)
JP (1) JP4601176B2 (pt)
KR (2) KR100685106B1 (pt)
CN (2) CN1212152C (pt)
AR (1) AR022251A1 (pt)
AT (1) ATE242002T1 (pt)
AU (1) AU771964B2 (pt)
BG (1) BG65556B1 (pt)
BR (1) BR0008182A (pt)
CA (1) CA2356737C (pt)
CZ (1) CZ302866B6 (pt)
DE (1) DE60003152T2 (pt)
DK (1) DK1143997T3 (pt)
EA (1) EA003927B1 (pt)
EE (1) EE05543B1 (pt)
ES (1) ES2200808T3 (pt)
HK (2) HK1043059B (pt)
HU (1) HU226149B1 (pt)
IL (2) IL144413A0 (pt)
NO (1) NO328814B1 (pt)
NZ (1) NZ512585A (pt)
PL (1) PL204713B1 (pt)
PT (1) PT1143997E (pt)
SI (1) SI1143997T1 (pt)
SK (1) SK287313B6 (pt)
TR (1) TR200102107T2 (pt)
UA (1) UA78483C2 (pt)
WO (1) WO2000043031A1 (pt)
ZA (1) ZA200105263B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00549B (me) * 2001-01-29 2011-10-10 Serono Lab Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
ATE416783T1 (de) * 2003-02-07 2008-12-15 Austria Wirtschaftsserv Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
AU2005249504A1 (en) * 2004-05-28 2005-12-15 Laboratoires Serono Sa Use of IL-17 in the treatment of fertility-related disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
PT1919290E (pt) * 2005-07-12 2014-03-20 Ampio Pharmaceuticals Inc Métodos e produtos para tratamento de doenças
US8877186B2 (en) * 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
AU2010264524B2 (en) 2009-06-22 2015-03-19 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
WO2010151531A1 (en) * 2009-06-22 2010-12-29 Dmi Acquistion Corp. Methods and products for treatment of diseases
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
DE69233701T2 (de) * 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
TR200102107T2 (tr) 2001-12-21
IL144413A (en) 2009-05-04
EP1143997B1 (en) 2003-06-04
WO2000043031A1 (en) 2000-07-27
KR20010101397A (ko) 2001-11-14
ZA200105263B (en) 2002-06-26
SK10292001A3 (sk) 2001-12-03
HUP0105103A3 (en) 2004-08-30
HK1082690A1 (en) 2006-06-16
CN1212152C (zh) 2005-07-27
CN1337883A (zh) 2002-02-27
NO328814B1 (no) 2010-05-18
KR20060128056A (ko) 2006-12-13
JP2002535284A (ja) 2002-10-22
HU226149B1 (en) 2008-05-28
CN100594932C (zh) 2010-03-24
DE60003152T2 (de) 2004-03-25
CN1698894A (zh) 2005-11-23
PT1143997E (pt) 2003-10-31
AU771964B2 (en) 2004-04-08
SK287313B6 (sk) 2010-06-07
PL350002A1 (en) 2002-10-21
HK1043059B (zh) 2005-11-18
CA2356737C (en) 2010-03-23
EE200100378A (et) 2002-10-15
IL144413A0 (en) 2002-05-23
ATE242002T1 (de) 2003-06-15
PL204713B1 (pl) 2010-02-26
SI1143997T1 (en) 2003-12-31
US6663865B1 (en) 2003-12-16
US20040057954A1 (en) 2004-03-25
UA78483C2 (en) 2007-04-10
CZ20012656A3 (cs) 2002-02-13
BG105691A (en) 2002-02-28
NO20013577L (no) 2001-08-29
HUP0105103A2 (hu) 2002-04-29
JP4601176B2 (ja) 2010-12-22
EP1022027A1 (en) 2000-07-26
EP1143997A1 (en) 2001-10-17
AR022251A1 (es) 2002-09-04
EE05543B1 (et) 2012-06-15
EA003927B1 (ru) 2003-10-30
NZ512585A (en) 2003-08-29
ES2200808T3 (es) 2004-03-16
EA200100799A1 (ru) 2001-12-24
DK1143997T3 (da) 2003-09-15
BG65556B1 (bg) 2008-12-30
CA2356737A1 (en) 2000-07-27
DE60003152D1 (de) 2003-07-10
AU1997300A (en) 2000-08-07
KR100685106B1 (ko) 2007-02-22
CZ302866B6 (cs) 2011-12-21
HK1043059A1 (en) 2002-09-06
NO20013577D0 (no) 2001-07-19

Similar Documents

Publication Publication Date Title
BR0008182A (pt) Antagonistas do fator de necrose tumoral e seu uso em endometriose
EA200400337A1 (ru) Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
BR0308739A (pt) Tratamentos em combinação para doenças mediadas por quimiocina
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
BR0107683A (pt) Drospirenona para terapia de reposição de hormÈnio
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
ES2128735T3 (es) Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas.
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
NO20031323L (no) Peptid-baserte forbindelser
CA2360313A1 (en) Glucocorticoid receptor modulators
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
ATE334139T1 (de) 17 beta-nitro-11 beta-arylsteroide und deren derivate mit hormonalen agonist- oder antagonisteigenschaften
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
BRPI0410739A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)
Safieh-Garabedian et al. The role of cytokines and prostaglandin-E2 in thymulin induced hyperalgesia
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
WO2004007557A3 (en) Tf antagonist

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.